How to Cite
Abstract
Прогноз при минимальном раке молочной железы благоприятный (10-летняя выживаемость около 95%). Однако, в случаях высокой степени злокачественности или гиперэкспрессии Her-2/neu (3+) показатели выживаемости снижаются до 70-75%.References
Семиглазов В.Ф.,Семиглазов В.В., Клетцель А.Е. Неинвазивные и инвазивные опухоли молочной железы. Санкт-Петербург. — 2006. — С. 350.
Bardou V.J., Arpino G., Elledge R.M. et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases // J. Clin. Oncol. — 2003. — Vol. 21 (10). — P. 1973-1979.
Black D., Younger J., Martei Y et al. Recurrence risk in Tla-b, node-negative, HER2 positive breast cancer // Breast Cancer Res. Treat. — 2006. -100 ^рр! 1; abstr 2037).
Chia S., Norris B., Speers C. et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers // J. Clin. Oncol. — 2008. — Vol. 26. — P 5697-6704.
Cohen I., Perel E., Tepper R. et al. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients // Breast Cancer Res.Treat. — 1999. — Vol. 53(3). — P255-262.
Decensi A., Gandini S., Serrano D. et al. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users // J. Clin.Oncol. — 2007. — Vol. 25 (27). — P. 4201-4209.
Decensi A., Robertson C., Viale G. et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers // J. Natl. Cancer. Inst. — 2003. — Vol. 95 (11). — P 779-790.
Dowsett M., Allred C., Knox J. et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial // J. Clin. Oncol. — 2008.— Vol. 26 (7). — P. 1059-1065.
Goldhirsch A., Francis P., Castiglione-Gertsch M. et al. Taxanes as adjuvant for breast cancer // Lancet. — 2000. — Vol. 356. — P507 (letter).
Goldhirsch A., Ingle J.N. et al. Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011 // Ann. Oncol. — 2011. — Vol. 20 (8). — P. 1319-1329.
Gonzalez-Angulo A.M., Litton I.K., Broglio K.R. et al. High risk of recurrence for breast cancer patients with HER2-positive node negative tumors 1 cm or smaller // J. Clin. Oncol. — 2009. — Vol. 27. — P 5700-5706.
Joensuu H., Isola J., Lundin M. et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study // Clin. Cancer Res. — 2003. — Vol. 9 (3). — P 923930.
Lamy P.J., Pujol P., Thezenas S., Kramar A. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy // Breast Cancer Res.Treat. — 2002. -Vol. 76 (1). — P65-71.
Ravdin PM., Green S., Dorr T.M. et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study // J. Clin. Oncol. — 1992. — Vol. 10 (8). — P 1284-1291.
Slamon D.J., Pegram M.D., Lopez A., Konecny G. Trastuzumab and chemotherapeutics: drug interactions and synergies // Semin. Oncol. — 2000. — Vol. 27 (6). — P 21-2; discussion 92-100.
Slamon D.J., Press M.F. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers // J. Natl. Cancer Inst. — 2009. — Vol. 101 (9). — P615-618.
Tovey S.M., Brown S., Doughty J.C. et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumors // Br. J. Cancer. — 2009. — Vol. 100. — P. 680-683.
Viani G.A., Afonso S.L., Stefano E.J. et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials // BMC Cancer. — 2007. — Vol. 7. — P153.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...